Induction of Broadly Neutralising HCV Antibodies in Mice by Integration-Deficient Lentiviral Vector-Based Pseudotyped Particles

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Deng, Yao ^a   Guan, Jie ^a   Wen, Bo ^a,b   Zhu, Na ^a   Chen, Hong ^a   Song, Jindong ^a   Yang, Yang ^a   Wang, Yue ^a   Tan, Wenjie ^a  

^a BEIJING HOSPITAL   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPATITIS C ANTIBODY; HEPATITIS C VACCINE; INTEGRATION DEFICIENT LENTIVIRUS VECTOR; LENTIVIRUS VECTOR; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 3; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PROTECTION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PSEUDOTYPING; VACCINATION; VIRUS NEUTRALIZATION; ADENOVIRIDAE; ANIMAL; BLOOD; CELL LINE; GENE ORDER; GENE VECTOR; GENETICS; HEPACIVIRUS; IMMUNOLOGY; LENTIVIRINAE; ULTRASTRUCTURE; VIRION; VIRUS DNA CELL DNA INTERACTION;

HEPATITIS C VIRUS; MUS;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, NEUTRALIZING; CELL LINE; CROSS PROTECTION; FEMALE; GENE ORDER; GENETIC VECTORS; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HUMANS; IMMUNITY, HUMORAL; IMMUNIZATION; IMMUNOGLOBULIN G; LENTIVIRUS; MICE; VIRION; VIRUS INTEGRATION;

EID: 84876583777     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062684     Document Type: Article

References (45)

1. Strickland GT, El-Kamary SS, Klenerman P, Nicosia A, (2008) Hepatitis C vaccine: supply and demand. Lancet Infect Dis 8: 379-386.
2. Shimakami T, Lanford RE, Lemon SM, (2009) Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities. Curr Opin Pharmacol. 9(5): 537-44.
3. Dustin LB, Rice CM, (2007) Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol. 25: 71-99.
4. Halliday J, Klenerman P, Barnes E, (2011) Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines 10(5): 659-72.
5. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, et al. (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263-267.
6. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, et al. (1998) Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72: 9873-9880.
7. Kootstra NA, Verma IM, (2003) Gene therapy with viral vectors. Annu Rev Pharmacol Toxicol 43: 413-439.
8. Hu B, Tai A, Wang P, (2011) Immunization delivered by lentiviral vectors for cancer and infectious diseases. Immunol Rev. 239(1): 45-61.
9. Arce F, Rowe HM, Chain B, Lopes L, Collins MK, (2009) Lentiviral vectors transduce proliferating dendritic cell precursors leading to persistent antigen presentation and immunization. Mol Ther 17: 1643-1650.
10. Wanisch K, Yáñez-Muñoz RJ, (2009) Integration-deficient lentiviral vectors: a slow coming of age. Mol Ther. 17(8): 1316-32.
11. Yu MY, Bartosch B, Zhang P, Guo ZP, Renzi PM, et al. (2004) Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci U S A 101: 7705-7710.
12. Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, et al. (2007) Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U SA. 104: 6025-6030.
13. Fafi-Kremer S, Fofana I, Soulier E, Carolla P, Meuleman P, et al. (2010) Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus re-infection in liver transplantation. J Exp Med 207: 2019-2031.
14. Puig M, Major ME, Mihalik K, Feinstone SM, (2004) Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine 22 (8): 991-1000.
15. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, et al. (2008) Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14(1): 25-27.
16. Kuiken C, Simmonds P (2009) Nomenclature and numbering of the hepatitis C virus. Methods Mol. Biol. 510, 33-53.
17. Roy P, Noad R (2009) Virus-like particles as a vaccine delivery system: Myths and facts. Adv. Exp. Med. Biol. 655, 145-158.
18. Bartosch B, Dubuisson J, Cosset FL, (2003) Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 197: 633-642.
19. Zhang K, Tan W, Deng Y, Li J, Wu X, et al. (2008) Development of Infectious Pseudo-particle Harboring Three Subtypes Hepatitis C Virus Glycoproteins and Their Application in Neutralization Assays. Chinese Journal of Virology 24(4): 288-294.
20. Lavillette D, Tarr AW, Voisset C, Donot P, Bartosch B, et al. (2005) Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 41, 265-274.
21. Guan J, Wen B, Deng Y, Zhang K, Chen H, et al. (2011) Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes. Virol J. 8(1): 506.
22. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio Tet al, (1995) Possible mechanism involving T-lymphocyte response to nonstructural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346: 1006-1007.
23. Leavitt AD, Shiue L, Varmus HE (1993) Site-directed Mutagenesis of HIV- 1 Integrase Demonstrates Differential Effects on Integrase Functions in Vitro. J Bio Chem. 288(3)2113-9.
24. Wen B, Deng Y, Guan J, Yan W, Wang Y, et al. (2011) Signal peptide replacements enhance expression and secretion of hepatitis C virus envelope glycoproteins. Acta Biochim Biophys Sin 43 (2): 96-102.
25. Dreux M, Cosset FL (2009) Detection of neutralizing antibodies with HCV pseudoparticles (HCVpp). Methods Mol. Biol. 510, 427-438.
26. Bian T, Zhou Y, Bi S, Tan W, Wang Y, (2009) HCV envelope protein function is dependent on the peptides preceding the glycoproteins. Biochem Biophys Res Commun. 2 378(1): 118-22.
27. Deng Y, Zhang K, Tan W, Wang Y, Chen H, et al. (2009) A recombinant DNA and vaccinia virus prime-boost regimen induces potent long-term T-cell responses to HCV in BALB/c mice. Vaccine 27: 2085-2088.
28. Qi X, Gao Y, Lu R, Deng Y, Meng X, et al. (2011) Peptide Mapping of H-2d Restricted T-cell Epitope against Six Antigens of HIV-1 Subtype B'/C by ELISPOT Assay. Chinese Journal of Virology 27(1) 34-43.
29. Negri DR, Michelini Z, Bona R, Blasi M, Filati P, et al. (2011) Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity. Expert Opin Biol Ther. 11(6): 739-50.
30. Bartosch B, Bukh J, Meunier JC, Granier C, Engle RE, et al. (2003) In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A 100: 14199-14204.
31. Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, et al. (2004) Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A 101: 10149-10154.
32. Meunier JC, Engle RE, Faulk K, Zhao M, Bartosch B, et al. (2005) Evidence for cross-genotype neutralization of hepatitis C virus pseudoparticles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci U S A 102: 4560-4565.
33. Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, et al. (2007) Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U SA. 104: 6025-6030.
34. Houghton M, (2011) Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev. 239(1): 99-108.
35. Stamataki Z, Coates S, Evans MJ, Wininger M, Crawford K, et al. (2007) Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine 25, 7773-7784.
36. Lin Y, Kwon T, Polo J, Zhu YF, Coates S, et al. (2008) Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5. J. Virol. 82, 7492-7503.
37. Frey SE, Houghton M, Coates S, Abrignani S, Chien D, et al. (2010) Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine. 28(38): 6367-73.
38. Ray R, Meyer K, Banerjee A, Basu A, Coates S, et al. (2010) Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J. Infect. Dis. 202, 862-866.
39. Elmowalid GA, Qiao M, Jeong SH, Borg BB, Baumert TF, et al. (2007) Immunization with hepatitits C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci U S A 104: 8427-8432.
40. Folgori A, Capone S, Ruggeri L, Meola A, Sporeno E, et al. (2006) A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 12: 190-197.
41. Garrone P, Fluckiger AC, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, et al. (2011) A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci. Transl. Med. 3, 94ra71.
42. Coutant F, Frenkiel MP, Despres P, Charneau P, (2008) Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS One. 3(12): e3973.
43. Karwacz K, Mukherjee S, Apolonia L, Blundell MP, Bouma G, et al. (2009) Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy. J Virol 83: 3094-103.
44. Negri DR, Michelini Z, Baroncelli S, Spada M, Vendetti S, et al. (2007) Successful immunization with a single injection of non-integrating lentiviral vector. Mol Ther 15: 1716-23.
45. Hu B, Dai B, Wang P, (2010) Vaccines delivered by integration-deficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity. Vaccine 28: 6675-83.